BioSoteria

From left to right: Hugh Tilson, MD, DrPH; Marianna Tran, PhD, MBA (retired); David Howell, PhD;
Alan Taylor, PhD; James Appleby, RPH, MPH; June Fallon, RN, MBA; Andrew Hindman, MBA (not shown)

Hugh H. Tilson, MD, DrPH (Board Chair)

Hugh Tilson M.D. (Washington University, St. Louis, Missouri 1964), DrPH (Harvard School of Public Health 1972) is a practicing epidemiologist and outcomes researcher, whose career in public health and preventive medicine spans 40 years. Fifteen years of public service included duties as a U.S. Army Preventive Medicine Officer in Germany; Consultant to the U.S. Office of Economic Opportunity, National Center for Health Services Research, and Veterans Administration; Local Public Health Officer and Human Services Director for Multnomah County (Portland), Oregon (NACHO President, 1976); and State Public Health Director for North Carolina.

Dr. Tilson then joined The Wellcome Foundation (now GlaxoSmithKline), where he introduced many epidemiologic principles and innovations. He applied public health in the private sector, most notably to the monitoring of safety of acyclovir and zidovudine.  Upon his retirement from GlaxoWellcome in 1996, Hugh joined the full-time clinical faculty of UNC School of Public Health in Chapel Hill. He is currently Adjunct Professor of Social Medicine at UNC and Medicine at Duke.

Dr. Tilson is an advisor to government and industry in health outcomes, drug safety, and evidence based health policy, including, most recently, public health preparedness. He was Founding Co-President of the International Society for Pharmacoepidemiology (ISPE) and a Founding Member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and of the Academy of Pharmaceutical Physicians and Investigators (APPI). He was a member of the Council for International Organisations for the Medical Sciences (CIOMS) working groups on Drug Safety from 1990 to 2001 and an advisor to the recent CIOMS VI and to the WHO Collaborating Centres. In the US, he chairs the National Steering Committee for the FDAMA-mandated Centers for Education and Research on Therapeutics (CERTs) program for AHRQ. He chairs the Policy Committee for the National Partnership for Prevention, recently chaired its Adult Immunization Roundtable, and currently co-chairs the task-force for CDC Goals and Objectives. He serves as senior advisor and epidemiologist for the international Antiretrovirals in Pregnancy Registry. He was a member of the recently adjourned Clinical Research Roundtable and has recently chaired two Study Committees, one on Safety of Therapeutic Devices in Children and more recently the International Board’s study on AIDS Prevention for Injection Drug Users for IOM of the National Academies of Science, where he has also been designated a Lifetime National Associate. He served as a consultant to IOM’s recent landmark study: “The Future of Drug Safety,” released in Fall, 2006.

June Fallon, RN, MBA

June Fallon is currently Vice President of Customer Program Development at McKesson Corporation. McKesson is a San Francisco based Fortune 15 company, focused on healthcare and pharmaceuticals.  In her current role, June is responsible for providing leadership and direction to the development of key strategic retail customer programs.  She works with various McKesson customer segments and McKesson business units to ensure steady and successful progress toward long and short term strategic goals and alignment of opportunities.  June’s key responsibilities include planning, developing and implementing multiple channel programs, and directing the development of company market requirements for specific products or programs.  One of her current primary projects is as a key member of the Medication Therapy Management Program (MTM) development team with responsibilities related to marketing, provider network development software and training.

June holds a B.S. from the College of St. Francis, and an MBA from Pepperdine University.  She has teaching credentials in business and industrial management and nursing.  She is an R.N. and has held a variety of management level positions in clinical settings involved in trauma, emergency and critical care. Her business career has spanned a number of domestic and international markets in the areas of major account sales management, strategic marketing and business development.

James C. Appleby, RPh, MPH

James Appleby is Executive Director of the Gerontological Society of America (GSA).  GSA is the nation’s oldest and largest interdisciplinary organization devoted to research, education, and practice in the field of aging. The principal mission of the Society — and its 5,000+ members — is to advance the study of aging and disseminate information among scientists, decision makers, and the general public. GSA’s structure also includes a policy institute, the National Academy on an Aging Society, and an educational branch, the Association of Gerontology in Higher Education.
Prior to joining GSA, Mr. Appleby had a 17 year career with the American Pharmacists Association (APhA), the 60,000 member professional association representing pharmacists.  He served in a variety of roles before being appointed Chief Operating Officer and Senior Vice President of Business Strategy and Operations.  In this capacity, he was responsible for managing the Association’s multiple business units and served as the senior executive responsible for the Association’s relationships with the pharmaceutical, chain drug, and wholesaler industries.

Prior to joining APhA, Mr. Appleby was on faculty at the Philadelphia College of Pharmacy and Science.  He has worked as a hospital pharmacist at the Presbyterian–University of Pennsylvania Medical Center and Jeanes Hospital in Philadelphia.  Mr. Appleby graduated with a bachelor of science in pharmacy from the Philadelphia College of Pharmacy and Science.  He also holds a master of public health degree from Temple University.  Mr. Appleby is a member of the District of Columbia Board of Pharmacy.

David Howell, PhD

David Howell is a self-employed clinical literature consultant. His earlier professional experiences include secondary education, filmmaking, intensive care respiratory therapy, and medical education. For the past 20 years, he has been in San Francisco. In the Bay Area, he has developed programs and literature for medical device companies, pharmaceutical companies, biomedical companies, and “virtual” business-to-business healthcare companies. He is the author of several book chapters and articles related to pulmonary care, neurology, aesthetic surgery, and business management. For his book on stroke, written for the American Pharmaceutical Association, Dr. Howell received the Eric Martin award for editorial excellence from the American Medical Writers Association.

He received his bachelor’s degree, master’s degree, and doctorate (Curriculum and Instruction) from the University of North Carolina at Chapel Hill.

Alan S. Taylor, Ph.D.

Alan S. Taylor is the former Vice President (VP) for Regulatory Affairs (RA) at Gilead Sciences. As VP-RA (1996-2006), Dr. Taylor was the company’s principle liaison to global health authorities and led the development and implementation of strategies to meet drug development, registration and post-marketing requirements of regulatory agencies. During his tenure, marketing authorizations were obtained for key Gilead antiviral medicines for the treatment of HIV, hepatitis B and influenza. As Gilead’s VP, Drug Assessment (1996-1999), Taylor was responsible for both RA and Toxicology, as well as for preclinical pharmacology, pharmacokinetic and toxicology studies required to support clinical development and marketing applications. Prior to joining Gilead, Dr. Taylor spent seven years with the US FDA. As Assistant Director for Pharmacology and Toxicology, Center for Drug Evaluation and Research (CDER), he was FDA’s lead representative to the ICH Safety Working Group, a government/industry collaboration that develops international guidelines for nonclinical safety studies and chaired CDER’s Carcinogenicity Assessment Committee. He began his FDA career as a Pharmacologist/Supervisory Pharmacologist in the Division of Oncology and Pulmonary Drug Products.

Andrew A. Hindman, MBA

Andrew A. Hindman is Vice President, Corporate Development at Onyx Pharmaceuticals, a position he has held since August 2008.  In this capacity, Mr. Hindman is responsible for leading Onyx’s efforts in securing external innovation to expand its product portfolio and catalyze the next phase of long-term growth for Onyx as a leading, independent biopharmaceutical company.  Prior to joining Onyx, Mr. Hindman worked at Gilead Sciences (1998-2008) where he served in a variety of roles of increasing responsibility during his tenure.  These roles included Hepatitis Franchise Global Commercial Lead and Project Leader, architecting the launch of Hepsera® (2001-2006) for treatment of chronic hepatitis B infection and development of franchise leadership for Gilead in the field of hepatology.  In addition, Mr. Hindman contributed significantly to Gilead’s early strategic and corporate development initiatives, including the acquisition of NeXstar Pharmaceuticals (1999), Triangle Pharmaceuticals (2002) and Myogen (2006).  Each of these transactions helped diversify and complement Gilead’s internal drug development and commercialization capabilities with external innovation to fuel Gilead’s long-term growth.  Prior to Gilead, Mr. Hindman helped establish the biotechnology investment banking franchise at J.P. Morgan, Inc.  Mr. Hindman holds an MBA from Columbia University and a BA (Biochemistry and Economics, with high honors) from Wesleyan University, Phi Beta Kappa.